“This FDA approval signals another important advancement in the evaluation of Alzheimer’s Disease. With every such achievement the molecular imaging community moves closer to a comprehensive arsenal of diagnostic and therapeutic tools to manage this formidable malady. With post-approval accessibility being of paramount importance, SOFIE continues to leverage its production capacity and expertise to ensure adequate supply of FDA approved compounds,” stated Trevor A. Subero, Vice President, Business Development, RCM

For more information: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease